Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review.
Joanne LundyOwen McKayDaniel CroaghVinod GanjuPublished in: JCO precision oncology (2022)